Mereo BioPharma (MREO) Non Operating Interest Expenses (2023 - 2026)

Mereo BioPharma (MREO) has reported Non Operating Interest Expenses for 4 consecutive years, with $16000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses fell 33.33% year-over-year to $16000.0 in Q2 2026; TTM through Jun 2026 was $87000.0, a 90.67% decrease from a year earlier, with the FY2025 full-year figure at $255000.0, down 81.39% from the prior year.
• Non Operating Interest Expenses was $16000.0 for Q2 2026 at Mereo BioPharma, down from $20000.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $1.0 million in Q2 2023 and troughed at $16000.0 in Q2 2026.
• A 4-year average of $324428.6 and a median of $320500.0 in 2024 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses rose 6.23% in 2024 and slumped 93.87% in 2025, its largest moves.
• Over 4 years, Non Operating Interest Expenses stood at $353000.0 in 2023, then advanced by 6.23% to $375000.0 in 2024, then tumbled by 93.87% to $23000.0 in 2025, then tumbled by 30.43% to $16000.0 in 2026.
• The last three Non Operating Interest Expenses figures came in at $16000.0 (Q2 2026), $20000.0 (Q1 2026), and $23000.0 (Q4 2025), per Business Quant data.